icu management of organophosphorus poisooing
Reading File
Finding Sources
Finding Sources
Searching PubMed
organophosphate poisoning ICU management
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I have comprehensive data now. Let me compile a structured, complete ICU management guide.
ICU Management of Organophosphorus (OP) Poisoning
Pathophysiology (Basis for Management)
OP compounds irreversibly phosphorylate acetylcholinesterase (AChE), causing ACh accumulation at all cholinergic synapses. This triggers a cholinergic crisis with:
- Muscarinic effects (parasympathetic nerve endings and sweat glands)
- Nicotinic effects (sympathetic ganglia, adrenal medulla, NMJ)
- CNS effects
Critical concept: "Aging" — after a variable period (minutes to >24 hours depending on the compound), the OP-AChE bond becomes permanent and oximes (pralidoxime) are rendered ineffective. New enzyme must be resynthesized over weeks.
Clinical Syndromes
| Syndrome | Timing | Features | Response to Antidotes |
|---|---|---|---|
| Acute cholinergic crisis | 0–24 h | SLUDGE + nicotinic + CNS | Atropine + pralidoxime |
| Intermediate syndrome | 24–96 h | Proximal limb, neck flexor, cranial nerve, respiratory muscle weakness | No response to antidotes |
| Delayed neuropathy (OPIDP) | 2–5 weeks | Distal sensorimotor polyneuropathy, then UMN signs | No treatment |
Recognition: Clinical Features
Muscarinic ("SLUDGE" / "DUMBELS")
| Mnemonic | Effect |
|---|---|
| Salivation, Lacrimation, Urination, Defecation, GI pain, Emesis | Hypersecretory state |
| "Killer Bs" | Bradycardia, Bronchorrhea, Bronchospasm — most lethal |
| Miosis | Hallmark eye finding |
Nicotinic
- Muscle fasciculations, cramps, weakness → respiratory muscle paralysis
- Tachycardia, hypertension, mydriasis, pallor (sympathetic ganglia)
- Mixed autonomic effects common (parasympathetic usually predominates)
CNS
- Anxiety, agitation, emotional lability
- Tremor, confusion, delirium, seizures
- Coma in severe poisoning (seizure activity may be masked by paralysis)
Death is most commonly from respiratory failure — bronchorrhea + respiratory muscle weakness + bronchospasm + aspiration.
ICU Management Algorithm
1. Decontamination (before everything else)
- Remove clothing (removes 80% of contamination) — protect staff with gloves/gown
- Skin/eye irrigation with water for ≥15 minutes
- Gastric lavage (within 1–2 hours of ingestion) if airway secured
- Activated charcoal: 1 g/kg PO/NG if not contraindicated (no vomiting/ileus, airway protected)
2. Airway & Ventilation (Priority)
- Early intubation is indicated for: excessive secretions, bronchospasm, respiratory muscle weakness, altered consciousness
- Use succinylcholine with caution — AChE inhibition prolongs neuromuscular blockade (may last hours); rocuronium preferred
- Avoid morphine, phenothiazines (exacerbate respiratory depression)
- Mechanical ventilation with lung-protective settings (ARDS protocol if aspiration pneumonitis occurs)
- Monitor for lipoid pneumonia — hydrocarbon solvents in pesticide preparations can cause this
3. Antidotes
A. Atropine (Muscarinic Antagonist) — FIRST-LINE, URGENT
Atropine blocks muscarinic receptors but does NOT reverse nicotinic effects or muscle weakness.
| Parameter | Dosing |
|---|---|
| Initial adult bolus | 2–4 mg IV (severe: up to 5 mg) every 5–10 min |
| Children | 0.02–0.05 mg/kg IV bolus |
| Titration target | Drying of secretions, clearing of chest; NOT pupil size or HR |
| Infusion | Once stabilized: 10–20% of total loading dose per hour |
| Total dose | Can reach 20–100+ mg in severe cases |
Endpoint of atropinization: Dry secretions, clear chest on auscultation, HR >80 bpm. NOT pupil dilation (this is a misleading endpoint).
B. Pralidoxime (2-PAM) — Oxime, Reactivates AChE
Regenerates phosphorylated AChE if given before aging occurs.
| Parameter | Dosing |
|---|---|
| Adult IV loading dose | 1–2 g IV over 15–30 min |
| Repeat | May repeat in 1–2 hr if muscle weakness persists, then q10–12 hr PRN |
| Continuous infusion | 0.5 g/hr (some guidelines: 8–10 mg/kg/hr) |
| Children | 20–50 mg/kg/dose (max 2 g) as load; then 10–20 mg/kg/hr infusion |
| IM | ≥40 kg: 600 mg IM, repeat q15 min up to 1800 mg total |
| Duration | Continue until no cholinergic signs for 12–24 h after cessation |
| Efficacy window | Most effective within first 24–48 h; ineffective after 36–48 h |
Important: Pralidoxime infusion must not exceed 200 mg/min (rapid infusion causes muscle rigidity, laryngospasm, tachycardia). Reduce dose in renal impairment (80–90% excreted unchanged in urine).
Combination (Duodote autoinjector): Pralidoxime 600 mg + Atropine 2.1 mg IM — used in mass casualty/field settings.
C. Benzodiazepines (Seizure Control)
- Diazepam 5–10 mg IV (or lorazepam 4 mg IV) for seizures
- Treat early — OP-induced seizures cause brain injury even when motor activity is absent due to paralysis
- Phenytoin is NOT effective for OP-induced seizures
D. Glycopyrrolate (Alternative to Atropine)
- Does not cross BBB → preferred by some for peripheral muscarinic control without CNS side effects
- Evidence: 2025 systematic review (PMID 38797902) supports its safety and efficacy
4. Monitoring Parameters in the ICU
| Parameter | Target/Notes |
|---|---|
| RBC cholinesterase (AChE) | Correlates with severity; <50% of normal = significant; <10% = severe |
| Plasma cholinesterase (BuChE) | Faster to measure, more sensitive but less specific |
| SpO₂ / ABG | Continuous |
| Chest auscultation | Main guide for atropine titration (secretions) |
| ECG | QTc prolongation, bradycardia, ventricular arrhythmias |
| Neuromuscular function | Fasciculations, grip strength, respiratory effort |
| Pupils | Miosis may persist even after adequate treatment |
5. Supportive ICU Care
| Issue | Management |
|---|---|
| Respiratory failure | Mechanical ventilation; watch for intermediate syndrome (days 1–4) |
| Seizures | IV benzodiazepines; EEG monitoring if paralyzed |
| Cardiovascular | Bradyarrhythmias: atropine; Torsades: MgSO₄, avoid QT-prolonging drugs |
| Pancreatitis/peritonitis | Abdominal pain workup; rare but described |
| Aspiration pneumonia | Broad-spectrum antibiotics; bronchoalveolar lavage if lipoid pneumonia |
| Rhabdomyolysis | IVF hydration, urine output monitoring |
| Hypoxic brain injury | Neuroprotective care if post-arrest |
6. Duration of ICU Care
- Most patients: cholinesterase levels recover within 48 hours with pralidoxime
- Symptomatic recovery with early treatment: ~10 days
- Fat-soluble compounds (e.g., fat-soluble OP pesticides): prolonged toxicity; may need weeks of respiratory support and continuous pralidoxime infusion
- End point of pralidoxime: absence of all signs/symptoms after drug is held
7. Intermediate Syndrome (Days 1–4)
- Occurs after the cholinergic crisis resolves
- Weakness of: proximal limbs, neck flexors, cranial nerve (III, IV, VI, VII, X, XII), respiratory muscles
- Not prevented or treated by atropine or pralidoxime — purely supportive ventilation
- Duration: 2–3 weeks; then resolves
8. Drugs to AVOID
| Drug | Reason |
|---|---|
| Succinylcholine | Prolonged paralysis (AChE inhibited) |
| Morphine | Respiratory depression, ganglionic stimulation |
| Phenothiazines | Lower seizure threshold |
| Phenytoin | Ineffective for OP seizures |
| Theophylline | May worsen seizures |
| QT-prolonging drugs | Arrhythmia risk (QTc already prolonged) |
Quick Reference Summary
OP Poisoning ICU Protocol:
1. DECONTAMINATE (staff protection first)
2. Airway/O₂ → early intubation if needed (use rocuronium)
3. ATROPINE — large doses, titrate to DRY chest (2–4 mg q5–10 min)
4. PRALIDOXIME — 1–2 g IV load, then infusion (start early, before aging)
5. BENZODIAZEPINES — for seizures
6. Monitor: RBC-AChE, ECG, neuro exam, chest
7. Watch for INTERMEDIATE SYNDROME (day 1–4) — needs ventilator support
8. Supportive care weeks if fat-soluble compound
Sources:
- Tintinalli's Emergency Medicine: A Comprehensive Study Guide, Chapter 201
- Adams and Victor's Principles of Neurology, 12th Ed., Chapter on Toxic Neuropathies
- Harriet Lane Handbook, 23rd Ed. — Pralidoxime dosing
- Goodman & Gilman's Pharmacological Basis of Therapeutics — OP pharmacology
- Rashid M et al. (2025). Glycopyrrolate in organophosphate/carbamate poisoning. Curr Rev Clin Exp Pharmacol. [PMID 38797902]
This is a shared conversation. Sign in to Orris to start your own chat.